• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小白菊内酯在小白菊中的溶液和固态稳定性以及辅料相容性

The solution and solid state stability and excipient compatibility of parthenolide in feverfew.

作者信息

Jin Ping, Madieh Shadi, Augsburger Larry L

机构信息

University of Maryland, Baltimore, School of Pharmacy, 20 N. Pine Street, Baltimore, MD 21201, USA.

出版信息

AAPS PharmSciTech. 2007 Dec 14;8(4):E105. doi: 10.1208/pt0804105.

DOI:10.1208/pt0804105
PMID:18181526
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2750358/
Abstract

The objectives of this research were to evaluate the stability of parthenolide in feverfew solution state and powdered feverfew (solid state), and explore the compatibility between commonly used excipients and parthenolide in feverfew. Feverfew extract solution was diluted with different pH buffers to study the solution stability of parthenolide in feverfew. Powdered feverfew extract was stored under 40 degrees C/0% approximately 75% relative humidities (RH) or 31% RH/5~50 degrees C to study the influence of temperature and relative humidity on the stability of parthenolide in feverfew solid state. Binary mixtures of feverfew powered extract and different excipients were stored at 50 degrees C/ 75% RH for excipient compatibility evaluation. The degradation of parthenolide in feverfew solution appears to fit a typical first-order reaction. Parthenolide is comparatively stable when the environmental pH is in the range of 5 to 7, becoming unstable when pH is less than 3 or more than 7. Parthenolide degradation in feverfew in the solid state does not fit any obvious reaction model. Moisture content and temperature both play important roles affecting the degradation rate. After 6 months of storage, parthenolide in feverfew remains constant at 5 degrees C/31% RH. However, approximately 40% parthenolide in feverfew can be degraded if stored at 50 degrees C/31% RH. When the moisture changed from 0% to 75% RH, the degradation of parthenolide in feverfew increased from 18% to 32% after 6-month storage under 40 degrees C. Parthenolide in feverfew exhibits good compatibility with commonly used excipients under stressed conditions in a 3-week screening study.

摘要

本研究的目的是评估小白菊内酯在小白菊溶液状态和小白菊粉末(固态)中的稳定性,并探索常用辅料与小白菊内酯在小白菊中的相容性。用不同pH缓冲液稀释小白菊提取物溶液,以研究小白菊内酯在小白菊中的溶液稳定性。将小白菊提取物粉末储存在40℃/0%至约75%相对湿度(RH)或31%RH/5至50℃条件下,以研究温度和相对湿度对小白菊内酯在小白菊固态稳定性的影响。将小白菊提取物粉末与不同辅料的二元混合物储存在50℃/75%RH条件下进行辅料相容性评估。小白菊内酯在小白菊溶液中的降解似乎符合典型的一级反应。当环境pH在5至7范围内时小白菊内酯相对稳定,当pH小于3或大于7时变得不稳定。小白菊内酯在小白菊固态中的降解不符合任何明显的反应模型。水分含量和温度都对降解速率起着重要作用。储存6个月后,小白菊内酯在5℃/31%RH条件下含量保持不变。然而,如果储存在50℃/31%RH条件下,小白菊中约40%的小白菊内酯会降解。当水分从0%变为75%RH时,在40℃下储存6个月后小白菊中小白菊内酯的降解率从18%增加到32%。在为期3周的筛选研究的强化条件下,小白菊内酯在小白菊中与常用辅料表现出良好的相容性。

相似文献

1
The solution and solid state stability and excipient compatibility of parthenolide in feverfew.小白菊内酯在小白菊中的溶液和固态稳定性以及辅料相容性
AAPS PharmSciTech. 2007 Dec 14;8(4):E105. doi: 10.1208/pt0804105.
2
The solution, solid state stability and kinetic investigation in degradation studies of lercanidipine: study of excipients compatibility of lercanidipine.乐卡地平的固态稳定性和降解研究中的动力学研究:乐卡地平辅料相容性研究。
Pharm Dev Technol. 2012 Nov-Dec;17(6):730-40. doi: 10.3109/10837450.2011.580758. Epub 2011 May 20.
3
5-Hydroxytryptamine-inhibiting property of Feverfew: role of parthenolide content.小白菊抑制5-羟色胺的特性:小白菊内酯含量的作用。
Acta Pharmacol Sin. 2000 Dec;21(12):1106-14.
4
Miniaturized approach for excipient selection during the development of oral solid dosage form.口服固体制剂研发过程中辅料选择的小型化方法
J Pharm Sci. 2014 Mar;103(3):900-8. doi: 10.1002/jps.23840. Epub 2014 Jan 16.
5
Parthenolide content and bioactivity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.). Estimation of commercial and authenticated feverfew products.小白菊(Tanacetum parthenium (L.) Schultz-Bip.)中小白菊内酯的含量及生物活性。市售及经鉴定的小白菊产品的评估。
J Pharm Pharmacol. 1992 May;44(5):391-5. doi: 10.1111/j.2042-7158.1992.tb03631.x.
6
Patch test reactivity to feverfew-containing creams in feverfew-allergic patients.对金盏花过敏患者使用含金盏花的乳膏进行斑贴试验反应。
Contact Dermatitis. 2010 Sep;63(3):146-50. doi: 10.1111/j.1600-0536.2010.01743.x.
7
Selected physical and chemical properties of Feverfew (Tanacetum parthenium) extracts important for formulated product quality and performance.小白菊(艾菊)提取物的特定物理和化学性质对制剂产品的质量和性能至关重要。
AAPS PharmSciTech. 2008;9(1):22-30. doi: 10.1208/s12249-007-9017-5. Epub 2008 Jan 4.
8
Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer.癌症患者中使用标准化剂量小白菊内酯的小白菊I期剂量递增试验。
Invest New Drugs. 2004 Aug;22(3):299-305. doi: 10.1023/B:DRUG.0000026256.38560.be.
9
Antiproliferative activities of parthenolide and golden feverfew extract against three human cancer cell lines.小白菊内酯和黄金叶提取物对三种人类癌细胞系的抗增殖活性。
J Med Food. 2006 Spring;9(1):55-61. doi: 10.1089/jmf.2006.9.55.
10
Investigating the Influence of Excipients on the Stability of Levothyroxine Sodium Pentahydrate.研究辅料对五水合左甲状腺素钠稳定性的影响。
Mol Pharm. 2021 Jul 5;18(7):2683-2693. doi: 10.1021/acs.molpharmaceut.1c00217. Epub 2021 Jun 1.

引用本文的文献

1
Research advances in natural sesquiterpene lactones: overcoming cancer drug resistance through modulation of key signaling pathways.天然倍半萜内酯的研究进展:通过调节关键信号通路克服癌症耐药性
Cancer Drug Resist. 2025 Mar 24;8:13. doi: 10.20517/cdr.2024.178. eCollection 2025.
2
Sesquiterpene lactones and cancer: new insight into antitumor and anti-inflammatory effects of parthenolide-derived Dimethylaminomicheliolide and Micheliolide.倍半萜内酯与癌症:对源自小白菊内酯的二甲基氨基米氏内酯和米氏内酯的抗肿瘤及抗炎作用的新见解
Front Pharmacol. 2025 Feb 20;16:1551115. doi: 10.3389/fphar.2025.1551115. eCollection 2025.
3
The antitumor effect of the novel agent MCL/ACT001 in pancreatic ductal adenocarcinoma.新型药物 MCL/ACT001 在胰腺导管腺癌中的抗肿瘤作用。
J Cancer Res Clin Oncol. 2023 Aug;149(9):5717-5728. doi: 10.1007/s00432-022-04542-9. Epub 2022 Dec 22.
4
Sesquiterpene Lactones and Cancer: New Insight into Antitumor and Anti-inflammatory Effects of Parthenolide-Derived Dimethylaminomicheliolide and Micheliolide.倍半萜内酯与癌症:青蒿素衍生的二甲氨基 Micheliaolide 和 Micheliolide 的抗肿瘤和抗炎作用的新见解。
Comput Math Methods Med. 2022 Jul 18;2022:3744837. doi: 10.1155/2022/3744837. eCollection 2022.
5
Looking for the Holy Grail-Drug Candidates for Glioblastoma Multiforme Chemotherapy.寻找多形性胶质母细胞瘤化疗的圣杯——候选药物
Biomedicines. 2022 Apr 26;10(5):1001. doi: 10.3390/biomedicines10051001.
6
ACT001 attenuates microglia-mediated neuroinflammation after traumatic brain injury via inhibiting AKT/NFκB/NLRP3 pathway.ACT001 通过抑制 AKT/NFκB/NLRP3 通路来减轻创伤性脑损伤后的小胶质细胞介导的神经炎症。
Cell Commun Signal. 2022 Apr 23;20(1):56. doi: 10.1186/s12964-022-00862-y.
7
Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies.小白菊内酯作为多种恶性肿瘤抗癌治疗的协同剂
Pharmaceuticals (Basel). 2020 Aug 14;13(8):194. doi: 10.3390/ph13080194.
8
ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.ACT001通过抑制胶质母细胞瘤中STAT3的磷酸化来降低PD-L1的表达。
Theranostics. 2020 May 1;10(13):5943-5956. doi: 10.7150/thno.41498. eCollection 2020.
9
Micheliolide Enhances Radiosensitivities of p53-Deficient Non-Small-Cell Lung Cancer via Promoting HIF-1α Degradation.米歇利醇内酯通过促进 HIF-1α 降解增强 p53 缺陷型非小细胞肺癌的放射敏感性。
Int J Mol Sci. 2020 May 11;21(9):3392. doi: 10.3390/ijms21093392.
10
All-stage precisional glioma targeted therapy enabled by a well-designed D-peptide.一种精心设计的D肽实现的全阶段精准胶质瘤靶向治疗。
Theranostics. 2020 Mar 4;10(9):4073-4087. doi: 10.7150/thno.41382. eCollection 2020.

本文引用的文献

1
Biodegradable microspheres for parenteral delivery.用于肠胃外给药的可生物降解微球。
Crit Rev Ther Drug Carrier Syst. 2005;22(6):535-602. doi: 10.1615/critrevtherdrugcarriersyst.v22.i6.20.
2
PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics.奥曲肽的聚乙二醇化:II. N端单聚乙二醇化对生物活性和药代动力学的影响。
Pharm Res. 2005 May;22(5):743-9. doi: 10.1007/s11095-005-2590-y. Epub 2005 May 17.
3
PEGylation of octreotide: I. Separation of positional isomers and stability against acylation by poly(D,L-lactide-co-glycolide).奥曲肽的聚乙二醇化:I. 位置异构体的分离及对聚(D,L-丙交酯-共-乙交酯)酰化的稳定性
Pharm Res. 2005 May;22(5):736-42. doi: 10.1007/s11095-005-2589-4. Epub 2005 May 17.
4
Impurity formation studies with peptide-loaded polymeric microspheres Part I. In vivo evaluation.载肽聚合物微球的杂质形成研究 第一部分:体内评估
Int J Pharm. 2005 Jun 13;297(1-2):50-61. doi: 10.1016/j.ijpharm.2005.02.035.
5
Impurity formation studies with peptide-loaded polymeric microspheres Part II. In vitro evaluation.载肽聚合物微球的杂质形成研究 第二部分。体外评估。
Int J Pharm. 2005 Jun 13;297(1-2):62-72. doi: 10.1016/j.ijpharm.2005.02.034.
6
Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles.克服可生物降解纳米和微粒内肽和蛋白质不稳定性的策略方法。
Eur J Pharm Biopharm. 2005 Apr;59(3):375-88. doi: 10.1016/j.ejpb.2004.10.006.
7
In vivo release kinetics of octreotide acetate from experimental polymeric microsphere formulations using oil/water and oil/oil processes.使用油/水和油/油工艺从实验性聚合物微球制剂中体内释放醋酸奥曲肽的动力学
AAPS PharmSciTech. 2004 Sep 30;5(3):e49. doi: 10.1208/pt050349.
8
Preparation and stability of poly(ethylene glycol) (PEG)ylated octreotide for application to microsphere delivery.用于微球递送的聚乙二醇(PEG)化奥曲肽的制备与稳定性
AAPS PharmSciTech. 2003 Dec 31;4(4):E72. doi: 10.1208/pt040472.
9
Identification of chemically modified peptide from poly(D,L-lactide-co-glycolide) microspheres under in vitro release conditions.在体外释放条件下从聚(D,L-丙交酯-共-乙交酯)微球中鉴定化学修饰肽
AAPS PharmSciTech. 2003 Oct 13;4(4):E50. doi: 10.1208/pt040450.
10
Direct determination of the peptide content in microspheres by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.通过基质辅助激光解吸/电离飞行时间质谱法直接测定微球中的肽含量。
Anal Chem. 2004 May 1;76(9):2669-73. doi: 10.1021/ac035477i.